Twenty patients reported sequelae of neuroendocrine disturbance after chemoradiotherapy; eight patients reported hormone replacement or pituitary hormone deficiency without details; and the remaining 12 patients primarily presented with persistent CDI, followed by central hypothyroidism, adrenocorticotropic and basal cortisol deficiency, growth hormone and IGF-1 deficiency, and hypogonadotropic hypogonadism. This evidence concerns the gene GH1 and hyperinsulinemic hypoglycemia, familial, 4.